CervoMed Statistics
Total Valuation
CervoMed has a market cap or net worth of $130.82 million. The enterprise value is $124.45 million.
| Market Cap | 130.82M |
| Enterprise Value | 124.45M |
Important Dates
The next estimated earnings date is Tuesday, August 6, 2024, after market close.
| Earnings Date | Aug 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
CervoMed has 8.25 million shares outstanding. The number of shares has increased by 1,090.89% in one year.
| Shares Outstanding | 8.25M |
| Shares Change (YoY) | +1,090.89% |
| Shares Change (QoQ) | +131.85% |
| Owned by Insiders (%) | 35.19% |
| Owned by Institutions (%) | 34.85% |
| Float | 3.79M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 20.56 |
| Forward PS | 20.69 |
| PB Ratio | 24.52 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 19.55 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.99, with zero debt.
| Current Ratio | 2.99 |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -53.00% and return on invested capital (ROIC) is -188.20%.
| Return on Equity (ROE) | -53.00% |
| Return on Assets (ROA) | -42.40% |
| Return on Capital (ROIC) | -188.20% |
| Revenue Per Employee | $795,539 |
| Profits Per Employee | -$604,934 |
| Employee Count | 8 |
| Asset Turnover | 0.56 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +230.21% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +230.21% |
| 50-Day Moving Average | 21.15 |
| 200-Day Moving Average | 14.10 |
| Relative Strength Index (RSI) | 31.21 |
| Average Volume (20 Days) | 102,350 |
Short Selling Information
The latest short interest is 181,892, so 2.20% of the outstanding shares have been sold short.
| Short Interest | 181,892 |
| Short Previous Month | 167,670 |
| Short % of Shares Out | 2.20% |
| Short % of Float | 4.80% |
| Short Ratio (days to cover) | 5.25 |
Income Statement
In the last 12 months, CervoMed had revenue of $6.36 million and -$4.84 million in losses. Loss per share was -$1.12.
| Revenue | 6.36M |
| Gross Profit | 6.36M |
| Operating Income | -10.04M |
| Pretax Income | -4.84M |
| Net Income | -4.84M |
| EBITDA | -4.84M |
| EBIT | -4.84M |
| Loss Per Share | -$1.12 |
Balance Sheet
The company has $6.37 million in cash and no debt, giving a net cash position of $6.37 million or $0.77 per share.
| Cash & Cash Equivalents | 6.37M |
| Total Debt | n/a |
| Net Cash | 6.37M |
| Net Cash Per Share | $0.77 |
| Equity (Book Value) | 5.34M |
| Book Value Per Share | 0.65 |
| Working Capital | 5.30M |
Cash Flow
| Operating Cash Flow | -3.91M |
| Capital Expenditures | n/a |
| Free Cash Flow | -3.91M |
| FCF Per Share | -$0.63 |
Margins
Gross margin is 100.00%, with operating and profit margins of -157.80% and -76.04%.
| Gross Margin | 100.00% |
| Operating Margin | -157.80% |
| Pretax Margin | -76.04% |
| Profit Margin | -76.04% |
| EBITDA Margin | -76.04% |
| EBIT Margin | -76.04% |
| FCF Margin | -61.36% |
Dividends & Yields
CervoMed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1,090.89% |
| Shareholder Yield | -1,090.89% |
| Earnings Yield | -3.70% |
| FCF Yield | -2.99% |
Analyst Forecast
The average price target for CervoMed is $67.50, which is 325.87% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $67.50 |
| Price Target Difference | 325.87% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 38.70% |
| EPS Growth Forecast (5Y) | 70.55% |
Stock Splits
The last stock split was on August 17, 2023. It was a reverse split with a ratio of 2:3.
| Last Split Date | Aug 17, 2023 |
| Split Type | Reverse |
| Split Ratio | 2:3 |
Scores
CervoMed has an Altman Z-Score of 19.12 and a Piotroski F-Score of 2.
| Altman Z-Score | 19.12 |
| Piotroski F-Score | 2 |